Global liquid
biopsies market is anticipated to reach 5,958.3 million by 2030, according
to a new report by Grand View Research, Inc. As these less invasive biopsies
are able to address a number of significant challenges associated with
conventional biopsies such as, high level of invasiveness, incompleteness of
cancer information that is acquired, associated post-biopsy serious medical
complications, and subsequent cost inclusions. A growing need for more
advanced, efficient and accurate method which provides a holistic view of the
tumor and metastasis is the prime factor fueling rapid development of liquid
biopsies.
The market has gained
considerable traction in the past couple of years. A number of clinical
research projects related to circulating tumor cells, and cell-free tumor DNA
have been initiated in the latter half of the past decade. As a result, there
are a number of ongoing clinical trials that are due to be completed between
post 2017-18. It is expected that upon successful completion, commercialization
of these assays and tests will provide the market a significant boost in
potential addressable target revenue and fuel growth through to 2030.
In-depth
research report on Liquid biopsy market - http://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market
Further key findings from the report suggest:
- In terms of applications, therapy selection of metastatic cancers is the key area of liquid biopsy usage as these provide significant insights into the unique genetic information encoded in CTCs and ctDNAs. Furthermore, with the addition of more research data reinforcing the usage of liquid biopsies over the coming years, it is expected that their application for molecular monitoring of diseases will also be a lucrative source of revenue through to 2030
- Key biomarkers that any liquid biopsy targets include circulating tumor cells, circulating tumor DNA and exosomes that are macrovesicles containing tumor RNA, or tumor protein freely circulating in the patient’s bloodstream. Assays for ctDNA are expected to account for the largest share of revenue through to 2030 owing to the currently present assays and expected number of products that are to be commercialized over the coming decade.
- Development of parallel multi-gene analysis using next generation sequencing technology is the underlying factor that has enabled oncologists to more efficiently sequence ctDNA and gain insights related to cancer metastasis and the related mechanism. This understanding provides a patient-centric systemic view of cancer and aids in its long term monitoring.
- North America, specifically the U.S. accounts for the largest share of revenue for the development of liquid biopsy market. The region was observed to account for around 50% of the global potential in 2015 owing to the high number clinical development projects underway for the commercialization of CTC and ctDNA assays till 2020. Furthermore, throughout the forecast period, U.S. is expected to dominate revenue generation owing to the dynamic nature & being the region of prime activity, research and development with respect to liquid biopsy and next generation sequencing technology.
- Although, post successful commercialization through to 2030, Asia Pacific is expected to be a lucrative region for development as it is expected to be characterized by the presence of a large patient population base, developing healthcare framework and growth in integration of more advanced healthcare practices.
- The market is in its developing phase and is characterized by the presence of a number of relatively smaller entities involved in innovation and new product development. Companies such as Biocept, Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant Health, Qiagen, Personal Genome Diagnostics, Cynvenio, RainDance Technologies, and Trovagene are operating in the space and have a number of commercialized assays in their portfolios for liquid biopsy.
- Furthermore, as this space has a high lucrative potential, and is considerably influenced by the developments in NGS technology, there are a number of major players that have ongoing investigational & observational clinical trials and are due to be completed by 2017 to 2019. Collectively, over 30 clinical trials are currently registered as active by companies including Illumina, Foundation Medicine, Natera Inc., Roche, Sequenom, LabCorp, Epic Sciences, and Pathway Genomics in the U.S. alone. Anticipated successful commercialization of these products is expected to fuel growth over the forecast period.
Global
Liquid Biopsy Outlook, by Application (Revenue, USD Million, 2013 - 2030)
- Therapy Selection for Metastatic Breast Cancer (MBS)
- Therapy Selection for Other Metastatic Cancer
- Molecular Health Monitoring
Global
Liquid Biopsy, by Sample Type (Revenue, USD Million, 2013 - 2030)
- Blood Sample based
- Urine Sample based
- Other Bio Fluids (Tissue fluids and Saliva) based
Global Liquid Biopsy Outlook, by Biomarker, (Revenue, USD
Million, 2013 - 2030)
- Circulating Tumor Cells (CTC)
- Circulating Tumor DNA (ctDNA)
- Exosomes
Global Liquid Biopsy Outlook, by Biomarker,
(Revenue, USD Million, 2013 - 2030)
- Multi
- gene - parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
Global Liquid Biopsy Market, Regional Outlook (Revenue,
USD Million, 2013 - 2030)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia
Pacific
- China
- Japan
- Latin
America
- Brazil
- MEA
- South Africa
Browse
more research reports of this category:
About
Grand View Research
Grand View Research,
Inc. is a U.S. based market research and consulting company, registered in the State
of California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, the company offers
market intelligence studies ensuring relevant and fact-based research across a
range of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment